131 related articles for article (PubMed ID: 31209481)
1. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
Lauper K; Mongin D; Alpizar-Rodriguez D; Codreanu C; Iannone F; Kristianslund EK; Kvien TK; Pavelka K; Pombo-Suarez M; Santos MJ; Gabay C; Finckh A; Courvoisier DS
Rheumatology (Oxford); 2019 Dec; 58(12):2221-2229. PubMed ID: 31209481
[TBL] [Abstract][Full Text] [Related]
2. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
Gabay C; Riek M; Scherer A; Finckh A;
Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
[TBL] [Abstract][Full Text] [Related]
5. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
Gülfe A; Wallman JK; Kristensen LE
Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
[TBL] [Abstract][Full Text] [Related]
6. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Iannone F; Zavada J; Morel J; Gottenberg JE; Hyrich KL; Listing J
Ann Rheum Dis; 2017 Feb; 76(2):386-391. PubMed ID: 27307502
[TBL] [Abstract][Full Text] [Related]
7. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg JE; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordström DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Rheumatology (Oxford); 2021 Feb; 60(2):820-828. PubMed ID: 32810263
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
[TBL] [Abstract][Full Text] [Related]
9. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
10. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
11. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
13. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
Forsblad-d'Elia H; Bengtsson K; Kristensen LE; Jacobsson LT
Rheumatology (Oxford); 2015 Jul; 54(7):1186-93. PubMed ID: 25505001
[TBL] [Abstract][Full Text] [Related]
14. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
[TBL] [Abstract][Full Text] [Related]
15. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
17. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
